Spero Therapeutics, Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Spero Therapeutics filed an 8-K on 2026-08-28 reporting entry into a Material Definitive Agreement (Item 1.01) and other events (Item 8.01). However, the filing text provided contains only metadata and document structure; no actual agreement terms, counterparty name, dollar amounts, share counts, dates, or business impact details are present in the excerpt.
Why this rating
Cannot assess significance without agreement details. Material agreement flagging suggests real event, but lack of concrete terms, counterparty, and financial data prevents meaningful evaluation relative to $160M company scale.
Extracted items
- 1.01 material agreement
- 8.01 other event
- 9.01 exhibits
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.